|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||4.02 - 4.34|
|52 Week Range||3.08 - 12.12|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||0.00 (0.00%)|
|1y Target Est||9.00|
VANCOUVER, British Columbia, Jan. 30, 2018-- Novelion Therapeutics Inc., a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, today ...
A federal judge on Tuesday sentenced Aegerion Pharmaceuticals Inc for improperly marketing a cholesterol drug and ordered that some of the $40.1 million it agreed to pay to resolve a U.S. investigation go to the company's victims. U.S. District Judge William Young in Boston had in November rejected an initial plea deal between the U.S. Justice Department and the Novelion Therapeutics Inc unit, saying it restricted his ability to impose a sentence. The judge sentenced Aegerion under a new deal that gave him discretion to determine how much it should pay.
U.S. District Judge William Young of Boston said in November that the original plea deal essentially restricted him to impose only the sentence agreed to by the U.S. Justice Department and Aegerion, a unit of Novelion Therapeutics Inc. Young said the earlier plea deal reflected the "shocking disparity between the treatment of corporations and individuals in our criminal justice system." He noted people typically go before judges with wide discretion to impose a sentence. Prosecutors said after Aegerion in 2012 received U.S. Food and Drug Administration approval to market Juxtapid for treating high cholesterol in people with a rare genetic disease, the company promoted the expensive drug for patients who lacked the condition.
VANCOUVER, British Columbia, Jan. 24, 2018-- Novelion Therapeutics Inc., a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, today ...
If you are a shareholder in Novelion Therapeutics Inc’s (NASDAQ:NVLN), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...
Cambridge-based Aegerion Pharmaceuticals said Thursday that a federal judge’s decision to reject its $40 million plea deal in a drug misbranding case has thrown the company into financial turmoil. In a court filing, lawyers for Aegerion asked the judge to quickly approve a new deal that the company plans to formally submit by Jan. 5. The previous agreement , under which Aegerion was to plead guilty to two misdemeanors, was rejected in November after the judge complained that it did not give him discretion to impose a sentence.
Aegerion Pharmaceuticals Inc has asked a U.S. judge to quickly approve a new plea agreement aimed at resolving probes into its promotion of a cholesterol drug, saying its parent company has been blocked from capital markets due to the case's uncertainty. The Novelion Therapeutics Inc unit asked U.S. District Judge William Young in Boston on Thursday to schedule a hearing so it can plead guilty to any new deal aimed at overcoming his objections to an earlier one. The initial deal in September called for Aegerion to plead guilty to two misdemeanor drug violations involving misbranding under the Food, Drug and Cosmetic Act and pay $40.1 million to resolve U.S. investigations.
Novelion Therapeutics Inc (NASDAQ:NVLN), a USD$63.60M small-cap, operates in the healthcare industry, which has experienced tailwinds from issues such as higher demand driven by an aging population and the increasingRead More...
VANCOUVER, British Columbia, Dec. 04, 2017-- Novelion Therapeutics Inc., a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, today ...
Investors are always looking for growth in small-cap stocks like Novelion Therapeutics Inc (NASDAQ:NVLN), with a market cap of USD $70.32M. However, an important fact which most ignore is: howRead More...
Novelion Therapeutics Inc (NASDAQ:NVLN), a biotechnology company based in Canada, saw significant share price volatility over the past couple of months on the NasdaqGS, rising to the highs of $7.76Read More...
The Vancouver, British Columbia-based company said it had a loss of $2.67 per share. Losses, adjusted for non-recurring costs and amortization costs, came to 89 cents per share. The retinal disease treatment ...
The U.S. Justice Department on Wednesday unveiled a revised a plea agreement with Aegerion Pharmaceuticals Inc that aimed to appease a federal judge who threatened to reject an earlier version that was part of a $36 million settlement. In court papers, prosecutors said they had sought to bolster the plea deal by adding probation of three to five years and a restriction on Aegerion and its employees from denying the factual basis of its eventual guilty plea. It was unclear if the new conditions would garner approval from Young, who noted at the October hearing that he had in prior cases criticized plea agreements that made the parties' sentencing recommendations binding on the court.
A U.S. judge on Wednesday said he may reject a plea agreement that was part of Aegerion Pharmaceuticals Inc's recent $36 million settlement with the U.S. Justice Department, saying he was not happy with its sentencing terms. U.S. District Judge William Young at a court hearing in Boston held off on definitively not accepting the deal, in which the Novelion Therapeutics Inc unit would plead guilty to two misdemeanors related to its marketing of an expensive cholesterol drug.
LONDON, UK / ACCESSWIRE / September 26, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Novelion Therapeutics Inc. (NASDAQ: NVLN ) ("Novelion"), ...
A U.S. charity that offers assistance to patients seeking help to cover out-of-pocket drug costs on Monday said it has been contacted in a connection with federal investigation into drugmakers' financial support of non-profits like itself. Patient Services Inc's disclosure came after the U.S. Justice Department on Friday said one of its donors, Aegerion Pharmaceuticals Inc, illegally used the non-profit to defray co-payments for patients prescribed an expensive cholesterol drug. The Justice Department made that claim in papers filed in Boston federal court as part of Aegerion's agreement to plead guilty to two misdemeanors and pay $40.1 million to resolve probes into its marketing of the drug, Juxtapid.
Aegerion Pharmaceuticals Inc will plead guilty to two misdemeanors and pay $40.1 million to resolve investigations into its marketing and sales of an expensive cholesterol drug, U.S. authorities said on Friday. The settlements will resolve long-running investigations into Aegerion, a subsidiary of Canada's Novelion Therapeutics Inc, by the U.S. Justice Department and the U.S. Securities and Exchange Commission related to its drug Juxtapid. Under the agreements, Aegerion will plead guilty to two misdemeanor drug misbranding violations of the Food, Drug and Cosmetic Act, pay $36 million to resolve cases by the Justice Department and pay $4.1 million to settle the SEC's lawsuit.